NCT05465759

Brief Summary

Assessment the frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2022

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

July 13, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 20, 2022

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2023

Completed
Last Updated

July 20, 2022

Status Verified

July 1, 2022

Enrollment Period

1 year

First QC Date

July 13, 2022

Last Update Submit

July 18, 2022

Conditions

COVID-19

Outcome Measures

Primary Outcomes (1)

  • calculate the frequency of SARS-CoV-2 infection among patients with malignant data collection during the study period

    To calculate the rate of SARS-CoV-2 infection among patients with malignant data collection within covid-19 pandemic either retrospective or prospective. Data will include : patient demography such as Age,sex,smoking status,cancer type cancer treatment (patient on chemotherapy or radiotherapy if available), symptoms, signs and laboratory parameters of COVID -19. outcome including hospitalization or ICU admission and mortality rate will be recorded

    1 year

Interventions

diseaseOTHER

Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients at south Egypt cancer institute

You may qualify if:

  • Malignant patients.
  • PCR positive for covid-19

You may not qualify if:

  • PCR negative for covid-19

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Central Study Contacts

mahmoud ahmed agamy, post graduate

CONTACT

01017989744mahmoudahmedatm@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

July 13, 2022

First Posted

July 20, 2022

Study Start

July 1, 2022

Primary Completion

July 1, 2023

Study Completion

August 1, 2023

Last Updated

July 20, 2022

Record last verified: 2022-07